{
  "source": "PA-Notification-Imbruvica.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1124-15\nProgram Prior Authorization/Notification\nMedication Imbruvica® (ibrutinib)\nP&T Approval Date 2/2014, 2/2015, 4/2015, 4/2016, 3/2017, 9/2017, 9/2018, 9/2019, 9/2020,\n10/2021, 10/2022, 10/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nImbruvica® (ibrutinib) is a kinase inhibitor indicated for the treatment of adult patients with the\nfollowing: chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL); chronic\nlymphocytic leukemia (CLL)/SLL with 17p deletion; and Waldenström’s macroglobulinemia\n(WM). Imbruvica is also FDA approved for the treatment of adult and pediatric patients age 1 year\nand older with chronic graft versus host disease (cGVHD) after failure of one or more lines of\nsystemic therapy.1\nThe National Cancer Comprehensive Network (NCCN) also recommends the use of Imbruvica for\nthe B-cell lymphoma types: extranodal marginal zone lymphoma (EMZL) of the stomach and of\nnongastric sites (noncutaneous), mantle cell lymphoma (MCL), diffuse large B-cell, HIV-related B-\ncell, high grade B-cell lymphoma, and post-transplant lymphoproliferative disorders. NCCN also\nrecommends its use for primary CNS lymphoma and hairy cell leukemia.2\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of 19\nyears, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or under\nsome circumstances. Some states also mandate usage of other Compendium references. Where such\nmandates apply, they supersede language in the benefit document or in the notification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Imbruvica will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. B-Cell Lymphoma\n1. Initial Authorization\na. Imbruv",
    ". Imbruvica will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. B-Cell Lymphoma\n1. Initial Authorization\na. Imbruvica will be approved based on one of the following criteria:\ni. Both of the following:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(a) Diagnosis of mantle cell lymphoma (MCL)\n-AND-\n(b) One of the following:\ni. Patient has received at least one prior therapy for MCL\nii. Used in pre-treatment therapy in combination with Rituxan (rituximab)\nto limit the number of cycles with RHyperCVAD (rituximab,\ncyclophosphamide, vincristine, doxorubicin, and dexamethasone)\nregimen\n-OR-\nii. Diagnosis of one of the following:\n(a) Chronic Lymphocytic Leukemia (CLL)\n(b) Small Lymphocytic Lymphoma (SLL)\n-OR-\niii. Both of the following:\n(a) Diagnosis of one of the following:\ni. Histologic transformation to diffuse large B-cell lymphoma\nii. Post-transplant lymphoproliferative disorders\niii. Extranodal marginal zone lymphoma (EMZL) of the stomach\niv. EMZL of nongastric sites (noncutaneous)\nv. Diffuse large B-cell lymphoma (non-GCB DLBCL and non-candidate\nfor transplant)\nvi. HIV-related B-cell lymphoma\nvii. High grade B-cell lymphoma\nviii. Hairy cell leukemia\nix. Nodal or splenic marginal zone lymphoma (MZL)\n-AND-\n(b) Used as second-line or a subsequent therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Imbruvica will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Imbruvica\ntherapy\n© 2024 UnitedHealthcare Services, Inc.\n2\nAuthorization will be issued for 12 months.\nC. Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma\n1. Initial Authorization\na. Imbruvica will be approved based on the following criterion:\n(1) Diagnosis of Waldenström's Macroglobulinemia/Lymphoplasmacytic\nLymphoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Imbruvica will be approved based on the following criterion",
    "1) Diagnosis of Waldenström's Macroglobulinemia/Lymphoplasmacytic\nLymphoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Imbruvica will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Imbruvica\ntherapy\nAuthorization will be issued for 12 months.\nD. Chronic Graft Versus Host Disease\n1. Initial Authorization\na. Imbruvica will be approved based on the following criterion:\n(1) Diagnosis of chronic graft versus host disease\n-AND-\n(2) History of failure of at least one other systemic therapy [e.g., corticosteroids,\nmycophenolate, etc.]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Imbruvica will be approved based on the following criterion:\n(1) Patient shows evidence of positive clinical response while on Imbruvica therapy\nAuthorization will be issued for 12 months.\nE. Primary CNS Lymphoma\n1. Initial Authorization\na. Imbruvica will be approved based on the following criterion:\n© 2024 UnitedHealthcare Services, Inc.\n3\n(1) Both of the following:\n(a) Diagnosis of primary CNS lymphoma\n-AND-\n(b) One of the following:\ni. Used as second-line or a subsequent therapy\nii. Used as induction therapy if patient is unsuitable or intolerant to high-\ndose methotrexate\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Imbruvica will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Imbruvica\ntherapy\nAuthorization will be issued for 12 months.\nF. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement progr",
    "months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim\nlogic. Use of automated approval and re-approval processes varies by program and/or\ntherapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Imbruvica [package insert]. South San Francisco, CA: Pharmacyclics, LLC. May 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/compendia-templates/compendia/drugs-and-biologics-compendia.\nAccessed September 11, 2024.\n© 2024 UnitedHealthcare Services, Inc.\n4\nProgram Prior Authorization/Notification - Imbruvica (ibrutinib)\nChange Control\n2/2014 New program for Imbruvica approved by FDA on 11/13/2013.\n9/2014 Administrative change - Tried/Failed exemption for State of New Jersey\nremoved.\n2/2015 Annual review. Added coverage for CLL with del(17p). Updated\nbackground and references.\n4/2015 Off-cycle review. Revised CLL/SLL and WM/Lymphoplasmacytic\nLymphoma per updated PI & NCCN.\n4/2016 Annual review. Moved MCL, CLL and SLL criteria under the general\ndiagnosis of NHL. Updated references.\n3/2017 Annual review. Added coverage for Marginal Zone Lymphoma (MZL).\nUpdated background and references.\n9/2017 Added new indication of chronic graft versus host disease. Updated\nbackground and references.\n9/2018 Annual review. Revised coverage criteria. Added coverage for B-Cell\nlymphoma types and CNS lymphoma. Updated background and\nreferences.\n9/2019 Annual review. Updated lymphoma based on NCCN guidelines.\nUpdated references. Added general NCCN recommended review\ncriteria.\n3/2020 Administrative change to correct formatting/numbering.\n9/2020 Annual review. Updat",
    "Updated lymphoma based on NCCN guidelines.\nUpdated references. Added general NCCN recommended review\ncriteria.\n3/2020 Administrative change to correct formatting/numbering.\n9/2020 Annual review. Updated lymphoma criteria based on NCCN guidelines.\nUpdated background and references.\n10/2021 Annual review. No changes to coverage criteria. Updated references.\n10/2022 Annual review. Updated background with approval for chronic graft-\nversus-host disease (cGVHD) for pediatric patients per prescribing\ninformation. Removed coverage for Follicular Lymphoma (grade 1-2)\nas no longer recommended by NCCN guidelines. Administrative\nchange to correct formatting/numbering. Added state mandate. Updated\nreferences.\n10/2023 Annual review. Updated background with withdrawal of MCL and\nMZL indications from FDA label as well as NCCN recommendations.\nUpdated B-Cell lymphomas with terminology changes. Updated\nreferences.\n10/2024 Annual review. No changes to coverage criteria. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n5"
  ]
}